IgG Autoantibodies against β2-Glycoprotein I Complexed with a Lipid Ligand Derived from Oxidized Low-Density Lipoprotein are Associated with Arterial Thrombosis in Antiphospholipid Syndrome

Daniel Lopez, Kazuko Kobayashi, Joan T. Merrill, Eiji Matsuura, Luis R. Lopez

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

We recently reported [J. Lipid Res. 42 (2001), 697; 43 (2002), 1486; 44 (2003), 716] that β2-glycoprotein I (β2GPI) forms complexes with oxidized LDL (oxLDL) and autoantibodies against these complexes are present in patients with SLE and antiphospholipid syndrome (APS). The relationship of β2GPI/oxLDL complexes and IgG autoantibodies against β2GPI complexed with oxLig-1 I (an oxLDL-derived defived ligand) with clinical manifestations of APS was studied in 150 APS and SLE patients. The β2GPI/oxLDL levels of APS patients were similar to those of SLE patients without APS, but they were significantly higher than healthy individuals. There was no difference in the complex levels among the patients with arterial, venous thrombosis, or pregnancy morbidity. IgG anti-β2GPI/oxLig-1 levels of APS were significantly higher than those of SLE without APS and healthy individuals. Further, antibody levels of APS patients with arterial thrombosis were significantly higher than those patients with venous thrombosis and pregnancy morbidity. Thus, oxidation of LDL leads the complex formation with β 2GPI in SLE and APS patients. In contrast, anti-β 2GPI/oxLig-1 autoantibodies were generated only in APS and were strongly associated with arterial thrombosis. These results suggest that autoantibodies against β2GPI/oxLDL complexes are etiologically important in the development of atherosclerosis in APS.

Original languageEnglish
Pages (from-to)203-211
Number of pages9
JournalClinical and Developmental Immunology
Volume10
Issue number2-4
DOIs
Publication statusPublished - Jun 2003

Fingerprint

Antiphospholipid Syndrome
Autoantibodies
Glycoproteins
Thrombosis
Immunoglobulin G
Ligands
Lipids
Venous Thrombosis
oxidized low density lipoprotein
Morbidity
Pregnancy
Atherosclerosis

Keywords

  • β-glycoprotein I
  • Anti-oxidized LDL antibodies
  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Arterial thrombosis
  • Atherosclerosis

ASJC Scopus subject areas

  • Immunology
  • Cell Biology
  • Developmental Biology

Cite this

@article{1ee23e06b662480ea2a68e5f7dcf4b65,
title = "IgG Autoantibodies against β2-Glycoprotein I Complexed with a Lipid Ligand Derived from Oxidized Low-Density Lipoprotein are Associated with Arterial Thrombosis in Antiphospholipid Syndrome",
abstract = "We recently reported [J. Lipid Res. 42 (2001), 697; 43 (2002), 1486; 44 (2003), 716] that β2-glycoprotein I (β2GPI) forms complexes with oxidized LDL (oxLDL) and autoantibodies against these complexes are present in patients with SLE and antiphospholipid syndrome (APS). The relationship of β2GPI/oxLDL complexes and IgG autoantibodies against β2GPI complexed with oxLig-1 I (an oxLDL-derived defived ligand) with clinical manifestations of APS was studied in 150 APS and SLE patients. The β2GPI/oxLDL levels of APS patients were similar to those of SLE patients without APS, but they were significantly higher than healthy individuals. There was no difference in the complex levels among the patients with arterial, venous thrombosis, or pregnancy morbidity. IgG anti-β2GPI/oxLig-1 levels of APS were significantly higher than those of SLE without APS and healthy individuals. Further, antibody levels of APS patients with arterial thrombosis were significantly higher than those patients with venous thrombosis and pregnancy morbidity. Thus, oxidation of LDL leads the complex formation with β 2GPI in SLE and APS patients. In contrast, anti-β 2GPI/oxLig-1 autoantibodies were generated only in APS and were strongly associated with arterial thrombosis. These results suggest that autoantibodies against β2GPI/oxLDL complexes are etiologically important in the development of atherosclerosis in APS.",
keywords = "β-glycoprotein I, Anti-oxidized LDL antibodies, Antiphospholipid antibodies, Antiphospholipid syndrome, Arterial thrombosis, Atherosclerosis",
author = "Daniel Lopez and Kazuko Kobayashi and Merrill, {Joan T.} and Eiji Matsuura and Lopez, {Luis R.}",
year = "2003",
month = "6",
doi = "10.1080/10446670310001642113",
language = "English",
volume = "10",
pages = "203--211",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Publishing Corporation",
number = "2-4",

}

TY - JOUR

T1 - IgG Autoantibodies against β2-Glycoprotein I Complexed with a Lipid Ligand Derived from Oxidized Low-Density Lipoprotein are Associated with Arterial Thrombosis in Antiphospholipid Syndrome

AU - Lopez, Daniel

AU - Kobayashi, Kazuko

AU - Merrill, Joan T.

AU - Matsuura, Eiji

AU - Lopez, Luis R.

PY - 2003/6

Y1 - 2003/6

N2 - We recently reported [J. Lipid Res. 42 (2001), 697; 43 (2002), 1486; 44 (2003), 716] that β2-glycoprotein I (β2GPI) forms complexes with oxidized LDL (oxLDL) and autoantibodies against these complexes are present in patients with SLE and antiphospholipid syndrome (APS). The relationship of β2GPI/oxLDL complexes and IgG autoantibodies against β2GPI complexed with oxLig-1 I (an oxLDL-derived defived ligand) with clinical manifestations of APS was studied in 150 APS and SLE patients. The β2GPI/oxLDL levels of APS patients were similar to those of SLE patients without APS, but they were significantly higher than healthy individuals. There was no difference in the complex levels among the patients with arterial, venous thrombosis, or pregnancy morbidity. IgG anti-β2GPI/oxLig-1 levels of APS were significantly higher than those of SLE without APS and healthy individuals. Further, antibody levels of APS patients with arterial thrombosis were significantly higher than those patients with venous thrombosis and pregnancy morbidity. Thus, oxidation of LDL leads the complex formation with β 2GPI in SLE and APS patients. In contrast, anti-β 2GPI/oxLig-1 autoantibodies were generated only in APS and were strongly associated with arterial thrombosis. These results suggest that autoantibodies against β2GPI/oxLDL complexes are etiologically important in the development of atherosclerosis in APS.

AB - We recently reported [J. Lipid Res. 42 (2001), 697; 43 (2002), 1486; 44 (2003), 716] that β2-glycoprotein I (β2GPI) forms complexes with oxidized LDL (oxLDL) and autoantibodies against these complexes are present in patients with SLE and antiphospholipid syndrome (APS). The relationship of β2GPI/oxLDL complexes and IgG autoantibodies against β2GPI complexed with oxLig-1 I (an oxLDL-derived defived ligand) with clinical manifestations of APS was studied in 150 APS and SLE patients. The β2GPI/oxLDL levels of APS patients were similar to those of SLE patients without APS, but they were significantly higher than healthy individuals. There was no difference in the complex levels among the patients with arterial, venous thrombosis, or pregnancy morbidity. IgG anti-β2GPI/oxLig-1 levels of APS were significantly higher than those of SLE without APS and healthy individuals. Further, antibody levels of APS patients with arterial thrombosis were significantly higher than those patients with venous thrombosis and pregnancy morbidity. Thus, oxidation of LDL leads the complex formation with β 2GPI in SLE and APS patients. In contrast, anti-β 2GPI/oxLig-1 autoantibodies were generated only in APS and were strongly associated with arterial thrombosis. These results suggest that autoantibodies against β2GPI/oxLDL complexes are etiologically important in the development of atherosclerosis in APS.

KW - β-glycoprotein I

KW - Anti-oxidized LDL antibodies

KW - Antiphospholipid antibodies

KW - Antiphospholipid syndrome

KW - Arterial thrombosis

KW - Atherosclerosis

UR - http://www.scopus.com/inward/record.url?scp=0347763341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347763341&partnerID=8YFLogxK

U2 - 10.1080/10446670310001642113

DO - 10.1080/10446670310001642113

M3 - Article

C2 - 14768953

AN - SCOPUS:0347763341

VL - 10

SP - 203

EP - 211

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

IS - 2-4

ER -